Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib

Abstract Previous studies demonstrated codon-specific KRAS mutation as a potential biomarker of resistance in metastatic colorectal cancer (mCRC). Our study aimed to evaluate the association of RAS status on survival in patients with mCRC treated with trifluridine/tipiracil (FTD/TPI) or regorafenib....

Descripció completa

Dades bibliogràfiques

Autors principals:	Meng-Che Hsieh, Kun-Ming Rau, Kuang-Wen Liu, Chong-Chi Chiu, Chih-I Chen, Ling-Chiao Song, Hsin-Pao Chen
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-01-01
Col·lecció:	Scientific Reports
Matèries:	Metastatic colorectal cancer Trifluridine/tipiracil RAS status
Accés en línia:	https://doi.org/10.1038/s41598-026-36509-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!